Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-23 pm EST			After market 07:59:30 pm
42.39 ^USD	+10.10%		43.56	+2.75%

Jan. 21	Sector Update: Health Care Stocks Higher Late Afternoon	MT
Jan. 21	Top Midday Gainers	MT

Leerink Partners Adjusts Moderna Price Target to $31 From $38, Maintains Underperform Rating

November 18, 2024 at 09:36 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Moderna, Inc.

Sector Update: Health Care Stocks Higher Late Afternoon	Jan. 21	MT
Top Midday Gainers	Jan. 21	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Jan. 21	MT
US Equity Indexes Rise as Treasury Yields Mixed After Trump Administration Avoids Fanning Inflation Expectations	Jan. 21	MT
Sector Update: Health Care	Jan. 21	MT
US Equity Indexes Rise in Midday Trading	Jan. 21	MT
Top Midday Stories: Charles Schwab's Adjusted Earnings Rise; Apple Q4 China Sales Reportedly Drop	Jan. 21	MT
Global markets live: Chevron, Amazon, GSK, Intel, Zalando...	Jan. 20
Moderna Lands $590 Million for Bird Flu Vaccine Development in US	Jan. 19	MT
Moderna Gets $590 Million of Federal Funding For Bird Flu Vaccine -- Update	Jan. 17	DJ
Moderna Gets $590 Million From US Government for Influenza Vaccine Program; Shares Rise After Hours	Jan. 17	MT
US awards Moderna $590 million for bird flu vaccine development	Jan. 17	RE
S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	Jan. 17	MT
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines	Jan. 17	DJ
Berenberg Bank Adjusts Moderna Price Target to $33 From $42, Maintains Hold Rating	Jan. 16	MT
Banks, bulls and tame inflation	Jan. 16
Analyst recommendations: Datadog, Estee Lauder, Netflix, Moderna, EasyJet...	Jan. 16
Moderna Struggles with COVID-19 Vaccine Market Share, Pipeline Progress, Morgan Stanley Says	Jan. 15	MT
Wall Street rallies on inflation and earnings bonanza	Jan. 15
Morgan Stanley Cuts Price Target on Moderna to $38 From $70, Keeps Equalweight Rating	Jan. 15	MT
Analyst recommendations: Adobe, Intuit, XPO, Netflix, Tesla...	Jan. 15
Leerink Partners Adjusts Moderna Price Target to $27 From $31, Maintains Underperform Rating	Jan. 14	MT
Stocks Gain Pre-Bell Ahead of Latest PPI Report; Asia, Europe Strong	Jan. 14	MT
MODERNA : Oddo BHF lowers its target price	Jan. 14	CF
Moderna, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM	Jan. 13

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Call

More about the company